Pulmonary arterial hypertension

Keros Therapeutics Halts Pulmonary Hypertension Drug After Safety Issues, Cuts 45% of Workforce

1 week ago talkbio0Tagged biotech sector, cibotercept, drug development halt, Financial cost, Financial savings, layoffs, PAH, Pericardial effusion, Pulmonary arterial hypertension

Keros Therapeutics; cibotercept; pulmonary arterial hypertension; PAH; layoffs; pericardial effusion; drug development halt; cost savings; biotech sector

Merck’s Winrevair Slashes Morbidity and Mortality Risk in Pulmonary Arterial Hypertension

2 months ago talkbio0Tagged Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III ZENITH trial, Pulmonary arterial hypertension, Winrevair

Winrevair, pulmonary arterial hypertension (PAH), Phase III ZENITH trial, morbidity, mortality, Merck

ACC25: Merck & Co.’s Winrevair reduces mortality in most severe PAH patients

2 months ago talkbio0Tagged Mortality Vital Statistics, Pulmonary arterial hypertension, Severe (severity modifier), Winrevair

Pulmonary arterial hypertension, Winrevair, Severe (severity modifier), Mortality Vital Statistics

Merck Halts HYPERION Trial of Winrevair Early Due to Overwhelming Efficacy in PAH Treatment

4 months ago talkbio0Tagged AKAP9 protein, human, Clinical Equipoise, Clinical Trials, Pulmonary arterial hypertension, sotatercept-csrk, Winrevair

Winrevair, sotatercept-csrk, pulmonary arterial hypertension (PAH), HYPERION trial, clinical equipoise, Merck, early trial termination

Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

4 months ago talkbio0Tagged Clinical Failure, Drug Development, IkT-001Pro, Inhibikase, Parkinson 's disease, Phase 2 Clinical Trials, Pulmonary arterial hypertension, risvodetinib

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro

Keros Therapeutics Halts Higher Dose Arms in PAH Trial Due to Pericardial Effusion Concerns

6 months ago talkbio0Tagged clinical trial safety, KER-012, Pericardial effusion, Pulmonary arterial hypertension, TROPOS

Keros Therapeutics, TROPOS trial, pulmonary arterial hypertension (PAH), cibotercept (KER-012), pericardial effusion, clinical trial safety

Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns

6 months ago talkbio0Tagged concerns, dosing, KER-012, PAH, Phase II TROPOS trial, Pulmonary arterial hypertension, Safety, Suspensions

Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial

Merck’s Winrevair Demonstrates Significant Mortality Benefit in Pulmonary Arterial Hypertension Patients

6 months ago talkbio0Tagged Benefit, Co., Mortality Vital Statistics, PAH, Pulmonary arterial hypertension, Sotatercept, Winrevair

Winrevair, Pulmonary Arterial Hypertension (PAH), Mortality Benefit, Sotatercept, Merck & Co.

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

6 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

Advancements in Pulmonary Hypertension and Interstitial Lung Disease: Emerging Therapies and Clinical Trial Designs

8 months ago talkbio0Tagged Clinical Trials, diagnostic tools, Lung Diseases, Interstitial, Pathogenesis, Phenotype, Pulmonary arterial hypertension, Pulmonary Hypertension

Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools